After Lexicon Pharmaceutical (LXRX) announced earlier that sotagliflozin 400 mg achieved the primary endpoint of superiority on A1C reduction versus placebo in the Phase 3 SOTA-EMPA study in type 2 diabetes, Stifel analyst Stephen Willey said he views the inability of sotagliflozin to demonstrate statistically superior HbA1c reduction versus Eli Lilly's (LLY) empagliflozin as a "relative disappointment" and "missed opportunity." The analyst, who had seen this trial as "the best remaining opportunity to establish commercial differentiation" in type 2 diabetes in a crowded field of selective SGLT2i drugs, keeps a Hold rating on Lexicon shares.